Clinical trial NCT01470794: Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Official title: A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Keywords: GBM
HGG
High grade glioma
Malignant glioma
Grade III glioma
Grad IV glioma
glioma
glioblastoma
Grade IV astrocytoma
brain cancer
recurrent glioblastoma
AA
AOD
anaplastic astrocytoma
Anaplastic oligodendroglioma
Anaplastic oligoastrocytoma
Lead sponsor: Tocagen Inc.
Sponsor class: INDUSTRY
First posted: 2011-11-11
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multicenter study evaluating the safety and tolerability of increasing doses of Toca 511, a retroviral replicating vector, injected into the resection cavity of patients with Grade III or Grade IV Gliomas who have elected to undergo surgical removal of their tumor. Approximately 6 weeks after injection of Toca 511, patients will begin an oral courses of Toca FC, an antifungal agent. These one week courses of Toca FC will be repeated during the approximately 30 week study. Two separate cohorts of patients treated with Toca 511 and Toca FC will also be evaluated with either of the following standard treatments for glioma: lomustine or bevacizumab. After completion of this study, all patients will be eligible for enrollment and encouraged to enter a long-term continuation protocol that enables additional Toca FC treatment cycles to be given, as well as permits the collection of long-term safety and survival data.


Eligibility criteria: Inclusion Criteria (must all be answered "Yes"):

* Has the patient given written informed consent?
* Is the patient between 18 years old and 80 years old inclusive?
* Has the patient had histologically proven HGG with recurrence or progression following initial definitive therapy(s) such as surgery with or without adjuvant radiation therapy and/or chemotherapy (confirmed by diagnostic biopsy or contrast-enhanced MRI and evaluable by Macdonald criteria)? Note if first recurrence of GBM is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field.
* Does the patient have a single, HGG tumor recurrence/progression that is ≤ 5 cm in its greatest dimension?
* Based on the pre-operative evaluation, is the tumor recurrence/progression a candidate for ≥ 80% resection?
* Has the patient elected not to undergo treatment with the Gliadel® wafer?
* Does the patient have a Karnofsky performance status ≥ 70?
* Does the patient have an absolute neutrophil count (ANC) ≥ 1500/mm3?
* Does the patient have an absolute lymphocyte count ≥ 500/mm3?
* Does the patient have a platelet count ≥ 100,000/mm3?
* Does the patient have a Hgb ≥ 10 g/dL?
* Does the patient have a normal PT/PTT? (subnormal PT/PTT acceptable)
* Does the patient have an estimated glomerular filtration rate of at least 50 mL/min (inclusive) by the Cockcroft-Gault formula?
* Does the patient have an ALT \< 3 times the upper limit of the laboratory reference range and total bilirubin \< 1.5 mg/dL?
* If the patient is a female of childbearing potential, has she had a negative serum pregnancy test within the past 21 days?
* Is the patient willing to use condoms for contraception for 6 months after receiving Toca 511 or until there is no evidence of the virus in his/her blood, whichever is longer. If the patient is a fertile female, is she willing to use contraception for at least 12 months?
* Is the patient willing and able to abide by the protocol?

Exclusion Criteria (must all be answered "No"):

* Has the patient received cytotoxic chemotherapy within the past 3 weeks (6 weeks for nitrosoureas) of the planned surgery date?
* Does the patient have, or has the subject had, within the past 4 weeks any infection requiring antibiotic, antifungal or antiviral therapy?
* Has the patient had a surgical procedure in the last 28 days or a surgical wound that is not healed?
* Does the patient have any bleeding diathesis, or must the subject take any anticoagulants, or antiplatelet agents, including NSAIDs that cannot be stopped for surgery?
* Does the patient have a history of allergy or intolerance to flucytosine?
* Is the patient HIV positive?
* Does the patient have any gastrointestinal disease that would prevent him or her from being able to ingest or absorb flucytosine?
* Has the patient received any investigational treatment within the past 30 days?
* Is the patient breast feeding?
* Has the patient received Avastin® (bevacizumab) for this recurrence/progression, or within the past 5 weeks?
* Does the patient have a history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than five years?

Primary outcomes:
measure: Dose Limiting Toxicities
timeFrame: 2 months
Secondary outcomes:
measure: Overall Survival of Subjects
timeFrame: Overall survival, Overall survival at 6 months (OS6), 9 months (OS9), and 12 months (OS12)
measure: Progression Free Survival (PFS) of Subjects
timeFrame: PFS of subjects at 6 months (PFS-6)
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA
state: California
city: San Diego
country: United States
facility: University of California at San Diego
state: California
city: Detroit
country: United States
facility: Henry Ford Hospital
state: Michigan
city: Edison
country: United States
facility: JFK Medical Center
state: New Jersey
city: Hackensack
country: United States
facility: Hackensack University Medical Center
state: New Jersey
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Seattle
country: United States
facility: Swedish Neuroscience Institute
state: Washington
Study officials:
affiliation: Tocagen Inc.
name: Asha Das, MD
role: STUDY_DIRECTOR
affiliation: University of California, Los Angeles
name: Timothy Cloughesy, MD, NO
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvao da Silva AP, Lin AH, Valenta DT, Perez OD, Ibanez CE, Chen CI, Pettersson PL, Burnett R, Daublebsky V, Hlavaty J, Gunzburg W, Kasahara N, Gruber HE, Jolly DJ, Robbins JM. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012 Feb;14(2):145-59. doi: 10.1093/neuonc/nor199. Epub 2011 Nov 9.
citation: Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018 Sep 3;20(10):1383-1392. doi: 10.1093/neuonc/noy075.